Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
FDA Grants Fast Track to Biogen’s Tau-Targeting BIIB080 for Alzheimer ...
BIIB080 Reduces Tau Biomarkers in Patients With Mild Alzheimer Disease
#AAIC21 - BIIB080 Safe, Lowered Tau Levels in Early Alzheimer's Patients
BIIB080 Significantly Reduces Tau Protein in Early Alzheimer Disease
BIIB080 Significantly Reduces Tau Protein in Early Alzheimer Disease ...
Exploratory analyses of clinical outcomes from the BIIB080 phase 1b ...
BIIB080 shows Alzheimer's-related tau protein reduction in study ...
Early Data From Ionis/Biogen’s BIIB080 Keeps Tau Alzheimer’s Hopes Alive
FDA Approves Vamorolone for DMD, Tau Agent BIIB080 Shows Promising ...
BIIB080 获 FDA 快速通道认证用于治疗阿尔茨海默病_tau_研究性_Biogen
BIIB080 for Alzheimer's Disease Clinical Trial 2024 | Power
Study on BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment ...
Biogen’s Investigational Tau-Targeting Therapy BIIB080
Biogen's Alzheimer's Innovation Pipeline: Lecanemab and BIIB080 as ...
Biogen’s BIIB080 Exhibits Favorable Outcomes in Phase 1b Trial for ...
Biogen's BIIB080 Receives FDA Fast Track Designation for Alzheimer's ...
UCSD Alzheimer's Disease Trial → Learn About the Safety of BIIB080 ...
Overview of therapeutic mechanisms targeting neuronal tau production ...
BIIB080, a MAPT-targeting antisense oligonucleotide, can reduce soluble ...
Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study ...
Biogen's tau-targeted antisense oligonucleotide therapy shows positive ...
IONIS-MAPTRx sodium (BIIB080 sodium) | Tau-lowering Antisense ...
Mechanism of Action and Potential of Anti-Tau Agent BIIB080: Ivana ...
Biogen Targets Alzheimer's Tau
Biogen continues to advance BIIB080, an antisense oligonucleotide ...
Frontiers | New Insights Into Drug Discovery Targeting Tau Protein
反义疗法挑战阿尔兹海默症！IONIS-MAPT Rx（BIIB080）在早期AD患者中显著降低了tau蛋白_腾讯新闻
Tau-targeting therapy in Alzheimer's disease: critical advances and ...
Ionis/渤健、Anlylam/再生元分别更新潜力ASO、siRNA治疗阿尔兹海默症的研究进展
渤健靶向Tau反义寡核苷酸疗法展现积极临床数据 - 知乎
阿尔茨海默病反义寡核苷酸疗法BIIB080再获积极成果 - 知乎
The Enigma of Tau Protein Aggregation: Mechanistic Insights and Future ...
Correcting tau isoform ratios with a long-acting antisense ...
The Interaction of Phosphorothioate-Containing RNA Targeted Drugs with ...
Nature Neurosci：一种有助于tau种子繁殖和神经毒性的蛋白|突触_新浪新闻
Design of a Phase 2, Randomized, Double‐Blind, Placebo‐Controlled ...
The development of Tau-targeted therapeutic agents | Download ...
2025年04月04日 バイオジェンのアルツハイマー病治療薬として開発中のタウを標的とするBIIB080がFDAのファストトラック指定を受ける
Identification and characterization of a MAPT-targeting locked nucleic ...
《JAMA·神经病学》：全球首个阿尔茨海默病基因沉默疗法让患者出现获益趋势，在25个月里多种tau蛋白水平持续下降！_生物科技_健康一线资讯
Biogen社、タウ標的アンチセンス薬BIIB080がアルツハイマー病対象にFDAからファストトラック指定を獲得：日経バイオテクONLINE
Biogen (BIIB) Stock Price & Overview
バイオジェンBIIB080、アルツハイマー治療薬としてファストトラック指定 | 製薬プレスDB
